文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

异基因造血干细胞移植治疗Shwachman-Diamond综合征三例报告并文献复习

[Allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a report of three cases and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

报告在浙江大学医学院附属第一医院接受异基因造血干细胞移植的3例Shwachman-Diamond综合征男性患者,移植年龄分别为32、33、32岁,均检出SBDS c.258+2T>C剪切位点杂合突变,均采用减低剂量预处理方案;例1移植后早期复发死亡,例2继发性植入不良依赖血小板输注,例3移植后脱离药物维持治疗血常规正常。

要点

  • 3例SDS患者均为男性,移植年龄分别为32、33、32岁,均幼年发病并身材矮小。
  • 3例均检出SBDS c.258+2T>C剪切位点杂合突变,家系成员均无SDS临床表现。
  • 例1移植前为MDS转化AML,移植后早期复发死亡;例2继发性植入不良;例3血常规正常。

核心结论

  • 报告3例SDS患者接受allo-HSCT的结局并结合文献总结SDS临床表现与基因突变特征,探讨allo-HSCT对此类患者的疗效及移植时机。

研究设计与样本

  • 研究报告在浙江大学医学院附属第一医院接受异基因造血干细胞移植的3例Shwachman-Diamond综合征患者,并结合相关文献资料进行总结。

主要发现

  • 3例患者均为男性,移植年龄分别为32、33、32岁,均为幼年发病。
  • 例1以贫血为首发临床表现后进展为全血细胞减少,例2和例3均以全血细胞减少为首发临床表现。
  • 例1和例3有智力障碍,例3有胰腺脂肪化及慢性胰腺炎表现,3例患者均身材矮小。
  • 3例患者均检出SBDS c.258+2T>C剪切位点杂合突变,家系成员均无SDS临床表现。
  • 例1移植前诊断骨髓增生异常综合征转化急性髓系白血病,移植后早期复发并死亡;例2为继发性植入不良、血小板输注依赖;例3移植后脱离药物维持治疗、血常规正常。

关键数值与推荐

  • 3例患者均采用减低剂量预处理方案(氟达拉滨+白消安+司莫司汀+兔抗人胸腺细胞免疫球蛋白)。
  • 例1和例2行单倍体造血干细胞移植,例3行无关供者造血干细胞移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study reports on three patients with Shwachman-Diamond syndrome (SDS) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the First Affiliated Hospital of Zhejiang University School of Medicine. Based on relevant literature, the clinical manifestations and genetic mutation characteristics of SDS were summarized, and the efficacy and timing of allo HSCT for such patients were explored. Three SDS patients were all male, with transplant ages of 32, 33, and 32 years old, respectively. All three patients were diagnosed in childhood. Case 1 presented with anemia as the initial clinical manifestation, which gradually progressed to a decrease in whole blood cells; Case 2 and 3 both present with a decrease in whole blood cells as the initial clinical manifestation. Case 1 and 3 have intellectual disabilities, while case 3 presents with pancreatic steatosis and chronic pancreatitis. All three patients have short stature. Three patients all detected heterozygous mutations in the SBDS: c.258+2T>C splice site. The family members of the three patients have no clinical manifestations of SDS. All three patients were treated with a reduced dose pre-treatment regimen (Fludarabine+Busulfan+Me-CCNU+Rabbit Anti-human Thymocyte Globulin). Case 1 and case 2 underwent haploid hematopoietic stem cell transplantation, while case 3 underwent unrelated donor hematopoietic stem cell transplantation. Case 1 was diagnosed with myelodysplastic syndrome transforming into acute myeloid leukemia before transplantation, but experienced early recurrence and death after transplantation; Case 2 is secondary implantation failure, dependent on platelet transfusion; Case 3 was removed from medication maintenance treatment after transplantation, and blood routine monitoring was normal. 研究报告了在浙江大学医学院附属第一医院接受异基因造血干细胞移植(allo-HSCT)的3例Shwachman-Diamond综合征(SDS)患者,并结合相关文献资料总结SDS的临床表现和基因突变特征,探讨allo-HSCT对此类患者的疗效及移植时机。3例SDS患者均为男性,移植年龄分别为32、33、32岁。3例患者均为幼年发病,例1以贫血为首发临床表现,后逐渐进展为全血细胞减少;例2、3均以全血细胞减少为首发临床表现。例1、3有智力障碍,例3有胰腺脂肪化及慢性胰腺炎表现。3例患者均身材矮小。3例患者均检出SBDS:c.258+2T>C剪切位点杂合突变。3例患者的家系成员均无SDS临床表现。3例患者均采用减低剂量预处理方案(氟达拉滨+白消安+司莫司汀+兔抗人胸腺细胞免疫球蛋白)。例1、例2行单倍体造血干细胞移植,例3行无关供者造血干细胞移植。例1移植前诊断骨髓增生异常综合征转化急性髓系白血病,移植后早期复发并死亡;例2为继发性植入不良,血小板输注依赖;例3移植后脱离药物维持治疗,血常规正常。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Feng AH, Shi JM, Fu HR, et al. [Allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a report of three cases and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39231775. doi:10.3760/cma.j.cn121090-20240107-00009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。